Why can t 1.2 million injections of anticancer drugs be covered by medical insurance?

Recently, the huge amount of "sky-high medicine" has been hyped on the Internet, causing heated discussions among the majority of netizens, in the final analysis, mainly because of this similar thing, related to the vital interests of the people, therefore, such a thing is indeed worthy of in-depth study**, from the analysis of the information obtained so far, I personally think that the country is based on the following considerations: <>

The first is fiscal pressure and fairness. On the one hand, the essence of medical insurance is the public welfare attribute, and the cost paid by residents is not high, most of the time they rely on financial subsidies, on the other hand, "sky-high drugs" are allowed to enter the scope of medical insurance, which is a waste of financial expenditure, and it is an unfair treatment for every taxpayer who pays medical insurance fees and even ordinary taxpayers, after all, We deeply understand a truth, drugs are expensive in research and development, not production, therefore, let the "sky-high price of drugs" come down, so that the masses of people can enjoy a relatively reasonable **, this is a responsible attitude to citizens, at the same time it can also greatly alleviate the pressure of medical insurance funds on financial payments, so that all aspects of the country's development have been relatively stable. <>

The second aspect is the clinical nature of 1.2 million injections of anticancer drugs. From the analysis of the information obtained so far, although it has entered the preliminary review stage, this does not mean that it can finally enter the formal negotiation, mainly because the clinical effect has not been absolutely guaranteed, it has only become an alternative, when the normal way can not ** patients, then it has a chance to appear, therefore, for this effect is not very prominent sky-high drugs, the factors that need to be considered can not be just because**, and it's** There is also no absolute advantage for it to be covered by medical insurance, so official caution is justified. <>

The reason why the 1.2 million anti-cancer drug cannot enter the medical insurance is because this drug is more expensive, and the drug cannot be lowered, and it is not economical.

Because this injection is particularly expensive, if it is reimbursed by the state, it may have a very heavy burden, so it is not included in the medical insurance.

This is because this anti-cancer drug is very expensive, and the cost of manufacturing is also very high, and it will bring a great burden to the country if it is entered into the medical insurance.

This is because the manufacturing cost of this anticancer drug is very high, and it is very expensive, so it cannot be covered by medical insurance.

Because this thing is really expensive, it has not entered the medical insurance until now. We should also be considerate of the country.

It's the annual medical insurance negotiation again, although the negotiators are as good as ever, but the 1.2 million anti-cancer drugs that everyone is thinking about still fail to negotiate and are not included in the medical insurance. <>

In fact, the failure of the negotiation of 1.2 million anti-cancer drugs is inevitable, in the medical insurance negotiations, the biggest advantage of negotiators is that the demand is relatively large, but the 1.2 million anti-cancer drugs are relatively targeted, and can only target specific ** or metastatic diffuse large B-cell lymphoma, and it needs to be customized, although the effect is very good, many people want to use it, but not everyone can use it. It can be seen from the bills circulating on the Internet that the sale of this anticancer drug is a certain biotechnology ****, not the designated hospital of the second level and above agreed in the insurance terms, so the 1.2 million anticancer drugs are purchased drugs in the medical insurance, and the insurance company's million medical insurance cannot be reimbursed, in this way, only by buying enough critical illness insurance can the anxiety caused by the 1.2 million anticancer drugs be resolved, after all, it is easier to buy 1.2 million insurance than to earn 1.2 million. <>

Although the insurance premium of 1.2 million critical illness is much less, if all the people in the family are equipped with 1.2 million critical illness protection, it is also a large expense, whether you suffer from diffuse large B-cell lymphoma is not necessarily, but the annual insurance premium must be paid, buy insurance to make life better, if you are poor because of buying insurance, it is not good, especially once one day the family is in a financial situation, and you can't pay the insurance premium to surrender the insurance, then the loss will be greater. <>

Not long ago, the China Banking and Insurance Regulatory Commission issued the "Notice on Further Regulating the Internet Life Insurance Business of Insurance Institutions", and it will be a good start to 2022 in more than a month, so some people want to take advantage of the supervision to hype a wave of sales stoppage. In fact, the purpose of the notice is mainly to standardize the sales process, forcing insurance companies to improve after-sales service, some insurance companies often engage in some "first month" 0 "yuan, long insurance short do" products to mislead consumers, insurance companies think they write very clearly, but in fact, ordinary people look like a book from heaven.

Because these anti-cancer drugs** are more expensive, and the production cost is also high, many drugs need to be imported, so they will not be covered by medical insurance.

Because the cost of this drug is so expensive, I can't get medical insurance, which I think is a normal thing, but I believe that it will improve in the future.

Because this is not in line with the relevant national regulations. **The high cost of anti-cancer drugs on medical insurance will increase the pressure on medical insurance in some aspects to a certain extent, and at the same time, it will make the country bear higher medical costs.

Summary. CAR-T is indeed a very good way, and the two CAR-T models that have been marketed in China are written for diffuse large B lymphoma (the most common one in lymphoma). Director Wu Huijing said that taking diffuse large B lymphoma after the failure of the second line ** as an example, the remission rate of CAR-T is 70%-90%, which is almost higher than that of all drugs, and the complete remission rate is 50%-60%.

However, about half of patients within 1 year**, even if a complete remission is achieved, there is still a chance of **.

1.2 million anti-imitation Tongfu cancer injection is not a scam to carry the bureau, 1.2 million yuan of anti-cancer drugs for a shot or let the cancer cells be cleared" Lunbi's report, this drug is called CAR-T drug, and the drug name is axileucel injection, which has been approved for marketing in China.

CAR-T is indeed a very good way, and the two CAR-T models that have been listed in China are both diffuse large B lymphoma (the most common one in lymphoma). Director Wu Huijing said that in the case of diffuse large B lymphoma after the failure of the second line, the remission rate of CAR-T is 70%-90%, which is almost higher than that of all drugs, and the complete remission rate is 50%-60%. However, about half of patients within 1 year**, even if a complete remission is achieved, there is still a chance of **.

Hello! This drug is currently not included in the medical insurance, if you want to use this drug, please see the following for specific methods:

It was learned from the Shenzhen Municipal Social Insurance Administration that the drugs included in the "Basic Medical Insurance Drug Catalog" emphasize that "they should be clinically necessary, safe and effective, reasonable, easy to use, and guaranteed by the market", which are reviewed and formulated by clinical medicine and pharmacy experts organized by the state nationwide. The clinical effects and ** of many imported new drugs that have not been recognized by the national competent authorities and are not included in the scope of the catalogue belong to self-financed drugs. This is very common in imported new anti-cancer drugs.

The basic medical insurance participants use Western medicine and Chinese patent medicine beyond the scope of the "basic medical insurance drug list", and the basic medical insurance ** will not pay the expenses incurred.

I don't think so. In other words, for the time being, this should not be possible. But in the near future, if there is, I think it should be possible. After all, our medical care. It's still very advanced.

This needle has not been clinically confirmed, but it is said that the local and short-term reduction of cancer cells does not cure the cancer. Therefore, drugs that do not have clinical trials cannot be included in medical insurance.

First of all, it is definitely impossible to be included in medical insurance in the short term, and the future can be expected, in fact, there are few indications for this drug, but it is only suitable for a small number of hematologic tumors, and the entity is basically useless, and cancer still needs to be detected and diagnosed early. There is hope in the early stage, and the late stage is basically just to prolong life.

So far, the sea will not include such a valuable drug in the scope of medical insurance, because the development of such drugs takes a long time, is time-consuming and labor-intensive, and cannot be mass-produced to meet the needs of the masses. So it can only be used by a small number of people.

Now it seems that this is not included in the scope of medical insurance reimbursement.

It is estimated that this drug will not be covered by medical insurance until 10 years later.